|

New Therapy to Stop Mesothelioma Tumor Growth

ByHolly Zink
New Therapy to Stop Mesothelioma Tumor Growth

Carbon-ion beam irradiation with cisplatin may stop the growth of malignant pleural mesothelioma.

Researchers at one of the world’s most experienced carbon ion therapy centers in Chiba, Japan shared that conclusion in a new article in the American Journal of Cancer Research.

New Treatment Strategy

Carbon-ion beam irradiation is a new treatment strategy for different cancer types. It has been used to treat cancer in patients for almost 30 years. It involves using a particle accelerator to pummel a tumor with DNA-damaging carbon ions.

Unlike conventional radiation, carbon ion therapy carries a lower risk of damaging healthy surrounding tissues since most of the energy is scattered as soon as the particles hit the cancer cells.

This could be especially useful for people with MPM since their tumors are close to vital organs like the lungs and heart. These tumors develop many decades after exposure to asbestos and have a high mortality rate.

Stop Tumor Growth

In this experiment, the researchers looked at what happened to tumor growth with carbon-ion beam irradiation alone and in combination with cisplatin. Cisplatin is a common chemotherapy drug used to treat mesothelioma and other cancers.

Tumors that were treated with only carbon-ion beam irradiation did show 90% less growth than untreated tumors. But they began growing again 17 weeks after radiation.

Tumors treated with carbon-ion beam irradiation and cisplatin stopped growing and even shrank in size. The researchers noticed that the tumors would still grow back after a few weeks, so they tried increasing the carbon-ion beam irradiation.

The researcher ultimately found a combination of carbon-ion beam irradiation and cisplatin that resulted in complete regression of the tumor with no regrowth.

If mesothelioma patients want to try carbon-ion beam irradiation therapy, they will have to travel. Although the technology was developed in the 1970s at Lawrence Berkeley National Laboratory in California, there are not yet any centers in the United States that are using it.

However, that will change in the next few years. The Mayo Clinic in Jacksonville, Florida is currently building the United States’ first carbon-ion beam irradiation therapy center.

Source:

Sai, Sei, Taiju Yamada, Keiko Ito, Nobuyuki Kanematsu, Masao Suzuki, Mitsuhiro Hayashi, and Masashi Koto. “Carbon-ion beam irradiation in combination with cisplatin effectively suppresses xenografted malignant pleural mesothelioma.” American Journal of Cancer Research 12, no. 12 (2022): 5657. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827089/

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…

  • | |

    Value of Mesothelioma Surgery Challenged for Healthy Patients

    ByAlex Strauss

    New research conducted in Italy and presented at the 15th World Conference on Lung Cancer in Sydney, Australia suggests that mesothelioma surgery – no matter what kind – may not offer a survival advantage over medical management for the healthiest of patients. Mesothelioma is a rare but aggressive malignancy that is highly resistant to standard cancer treatments. The two types of mesothelioma surgery considered to be options for people with resectable cancer are pleurectomy decortication (P/D) or extrapleural pneumonectomy (EPP). While EPP is more radical than P/D because it involves removing a lung, both carry a heavy risk of complications and, according to the Italian researchers, may not be of value for certain patients. The study reviewed data from 1,365…